menu
    • menu
    [{"orgOrder":0,"company":"BioVersys AG","sponsor":"CF AMR Syndicate","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"BV500","moa":"||CYP450","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioVersys AG \/ CF AMR Syndicate","highestDevelopmentStatusID":"2","companyTruncated":"BioVersys AG \/ CF AMR Syndicate"},{"orgOrder":0,"company":"Ethris","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ETH45","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ethris \/ Cipla","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Cipla"},{"orgOrder":0,"company":"Surrozen","sponsor":"TCGFB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Surrozen \/ TCGFB","highestDevelopmentStatusID":"2","companyTruncated":"Surrozen \/ TCGFB"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"The Jikei University","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AGC Biologics \/ The Jikei University","highestDevelopmentStatusID":"2","companyTruncated":"AGC Biologics \/ The Jikei University"},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Curadev Pharma Private Limited","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curadev Pharma Private Limited \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Curadev Pharma Private Limited \/ Bayer AG"},{"orgOrder":0,"company":"Affibody","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affibody \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Affibody \/ Chiesi Group"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ GSK","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ GSK"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Arda Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Arda Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arda Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"2","companyTruncated":"Arda Therapeutics \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Recursion Pharma \/ Bayer AG"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arda Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Arda Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : Andreessen Horowitz

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Arda Therapeutics Secures $43M Series A for Targeted Cell Depletion Therapies

                            Details : The proceeds will be used to advance targeted cell depletion therapies for the treatment of chronic diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : Andreessen Horowitz

                            Deal Size : $43.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : GSK

                            Deal Size : $7,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact

                            Details : The Flagship collaborates with GSK to discover and develop a portfolio of future transformational medicines and vaccines for the treatment of respiratory and immunology diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $150.0 million

                            July 29, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : GSK

                            Deal Size : $7,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioVersys AG

                            Switzerland arrow
                            EPSC
                            Not Confirmed

                            BioVersys AG

                            Switzerland arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BV500,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : CF AMR Syndicate

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BioVersys gets Non-Dilutive Funds from CF AMR Syndicate Collaborative Discovery Programme

                            Details : The proceeds will support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            June 04, 2024

                            Lead Product(s) : BV500,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : CF AMR Syndicate

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Surrozen

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Surrozen

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : TCGFB

                            Deal Size : $6.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Surrozen And TCGFB Collaborate on TGF-β Antibodies for Pulmonary Fibrosis

                            Details : The collaboration aims to discover antibody therapeutics targeting Transforming Growth Factor Beta (TGF-β) for the potential treatment of patients with idiopathic pulmonary fibrosis (IPF).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 11, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : TCGFB

                            Deal Size : $6.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : Chiesi Group

                            Deal Size : $214.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Affibody And Chiesi Group Collaborate To Develop And Commercialize Innovative Treatments For Respiratory Disea...

                            Details : Under the terms of the collaboration, Affibody and Chiesi Group will collaborate closely to progress up to three programs based on Affibody® molecules against undisclosed targets for respiratory diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 03, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : Chiesi Group

                            Deal Size : $214.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rubedo Life Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Rubedo Life Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBO-0618,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) ...

                            Details : The funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF), RBO-0618, targeting senescent lung stem cells.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 02, 2023

                            Lead Product(s) : RBO-0618,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AGC Biologics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : The Jikei University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IP...

                            Details : Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 04, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : The Jikei University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ethris

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Ethris

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH45,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : Cipla

                            Deal Size : $16.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cipla EU to Invest EUR 15 Million In Ethris, Initiating A Strategic Collaboration

                            Details : ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 29, 2022

                            Lead Product(s) : ETH45,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : Cipla

                            Deal Size : $16.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Recursion Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Recursion Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : Bayer AG

                            Deal Size : $1,030.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic ...

                            Details : The partnership will leverage Recursion’s purpose-built-AI-guided drug discovery platform and Bayer’s small molecule compound library and deep scientific expertise to discover and develop new treatments for fibrotic diseases of the lung, kidney, hear...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $30.0 million

                            September 09, 2020

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : Bayer AG

                            Deal Size : $1,030.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Curadev Pharma Private Limited

                            India arrow
                            EPSC
                            Not Confirmed

                            Curadev Pharma Private Limited

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : Bayer AG

                            Deal Size : $270.4 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across ...

                            Details : The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 23, 2020

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : Bayer AG

                            Deal Size : $270.4 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth